Following the success of HER-2-targeted therapy in HER-2 positive gastric cancer, several monoclonal antibodies and small molecules targeting other RTKs such as MET and FGFR2, along with their downstream signaling pathways, have been investigated [12,13,14,15,33,34]. This evidence concerns the gene MET and gastric cancer.